Last reviewed · How we verify
Triaxis, Sanofi Pasteur
At a glance
| Generic name | Triaxis, Sanofi Pasteur |
|---|---|
| Sponsor | Elke Leuridan, MD, PhD |
| Modality | Biologic |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Safety and Immunogenicity Study of Tdap Vaccinations for Plasma Donors (PHASE2)
- 10-year Follow-up After a Single Dose Acellular Pertussis Vaccination (PHASE4)
- The Optimal Timing of Vaccination in Pregnancy
- 5-year Follow-up After a Single Dose Acellular Pertussis Vaccination
- 2-year Follow-up After a Single Dose Acellular Pertussis Vaccination
- 3-year Follow-up After a Single Dose Acellular Pertussis Vaccination
- A Study of the Interaction Between BCG And MenC Immunisation: BAM (PHASE4)
- Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triaxis, Sanofi Pasteur CI brief — competitive landscape report
- Triaxis, Sanofi Pasteur updates RSS · CI watch RSS
- Elke Leuridan, MD, PhD portfolio CI